Management and Treatment of Prostatitis
Classification and Initial Diagnostic Approach
Prostatitis must be classified into one of four categories—acute bacterial prostatitis (NIH Category I), chronic bacterial prostatitis (NIH Category II), chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS, NIH Category III), or asymptomatic inflammatory prostatitis (NIH Category IV)—because each requires fundamentally different management strategies. 1
Acute Bacterial Prostatitis (NIH Category I)
Acute bacterial prostatitis presents with severe genitourinary pain (perineal, suprapubic, lower back, rectal, testicular, or penile tip), fever, chills, and systemic toxicity, caused by gram-negative bacteria in 80–97% of cases, most commonly E. coli, Klebsiella, or Pseudomonas. 2, 1
Critical diagnostic steps:
- Perform digital rectal examination gently only; vigorous prostatic massage is absolutely contraindicated because it can precipitate bacteremia and sepsis 1, 3
- Obtain midstream urine culture before antibiotics to identify the causative organism 1
- Collect blood cultures in febrile patients 1
- Order complete blood count to assess for leukocytosis 1
- Consider transrectal ultrasound only if prostatic abscess is suspected 1
Chronic Bacterial Prostatitis (NIH Category II)
Chronic bacterial prostatitis manifests as recurrent urinary tract infections from the same bacterial strain, with persistent or intermittent pelvic pain (perineum, suprapubic area, lower back, testicles, penile tip) and voiding disturbances (frequency, urgency, dysuria, incomplete emptying) lasting months to years. 1
The Meares-Stamey 4-glass test (first-void urine, midstream urine, expressed prostatic secretions, post-massage urine) is the gold standard for diagnosis, requiring a 10-fold higher bacterial count in expressed prostatic secretions compared to midstream urine. 1, 4 A simplified 2-specimen variant (midstream urine and expressed prostatic secretions only) can be used when the full test is impractical 1.
Up to 74% of chronic bacterial prostatitis cases are caused by gram-negative organisms, particularly E. coli, with other pathogens including Proteus mirabilis, Enterobacter species, and Serratia marcescens. 1
Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS, NIH Category III)
CP/CPPS is diagnosed when pelvic pain lasting ≥3 months of the preceding 6 months is present without documented uropathogenic infection on culture; typical pain locations include the perineum, suprapubic region, testicles, or penile tip, often worsened by urination or ejaculation. 1, 2
Many patients describe "pressure" or "discomfort" rather than overt pain and may deny pain when directly questioned; pain frequently intensifies after certain foods/beverages and with bladder filling, while voiding may provide relief. 1
CP/CPPS is not caused by a culturable infectious agent and requires symptom-focused management rather than antimicrobials. 1 The National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) measures symptom severity (scale 0-43), with a 6-point change considered clinically meaningful 2.
Treatment of Acute Bacterial Prostatitis
Outpatient Oral Therapy (Mild-to-Moderate Cases)
For patients able to tolerate oral medications without systemic toxicity or risk of urosepsis, ciprofloxacin 500-750 mg orally twice daily for 2-4 weeks is first-line therapy when local fluoroquinolone resistance is <10%. 1, 2 This regimen achieves a 92-97% success rate 2.
Levofloxacin 750 mg orally once daily for 2-4 weeks is an equally effective alternative with once-daily dosing. 1
For men younger than 35 years, add doxycycline 100 mg orally twice daily for 7 days to the fluoroquinolone regimen to cover atypical sexually transmitted pathogens (Chlamydia trachomatis, Neisseria gonorrhoeae, Mycoplasma species). 1 Alternatively, azithromycin 1 g orally as a single dose provides coverage for Mycoplasma 1.
Avoid amoxicillin or ampicillin empirically due to very high worldwide resistance rates. 1
Avoid trimethoprim-sulfamethoxazole empirically unless the organism is known to be susceptible, as resistance rates are high. 1
Inpatient Parenteral Therapy (Severe Cases)
Hospitalize patients who cannot tolerate oral medications, show signs of systemic toxicity or risk of urosepsis (which occurs in 7.3% of cases), or have suspected prostatic abscess. 1
Initiate intravenous therapy with one of the following regimens:
- Ciprofloxacin 400 mg IV twice daily 1
- Levofloxacin 750 mg IV once daily 1
- Ceftriaxone 1-2 g IV once daily (2 g preferred for complicated infections) 1
- Piperacillin-tazobactam 3.375-4.5 g IV every 6-8 hours 2
- Cefepime 1-2 g IV every 12 hours (higher dose for severe infections) 1
For healthcare-associated infections with suspected enterococci, use ampicillin, piperacillin-tazobactam, or vancomycin based on susceptibility; reserve carbapenems or novel broad-spectrum agents only when early culture results indicate multidrug-resistant organisms. 1
Transition to oral therapy once the patient is afebrile for ≥48 hours, hemodynamically stable, and culture results are available, completing a total 2-4 week course. 1
Assess clinical response after 48-72 hours of treatment; lack of improvement warrants imaging (ultrasound or CT) to exclude prostatic abscess or urinary obstruction. 1
Treatment of Chronic Bacterial Prostatitis
Chronic bacterial prostatitis requires prolonged antimicrobial therapy—a minimum of 4 weeks and up to 12 weeks—to prevent relapse, because shorter courses lead to high recurrence rates. 2, 4, 1
First-Line Therapy
Fluoroquinolones remain first-line therapy when local resistance is <10%:
- Ciprofloxacin 500-750 mg orally twice daily for 4-12 weeks 1, 4
- Levofloxacin 750 mg orally once daily for 4-12 weeks 1, 4
Avoid fluoroquinolones if local resistance exceeds 10% or if the patient has received them in the last 6 months. 1
Second-Line Therapy
Trimethoprim-sulfamethoxazole 160/800 mg orally twice daily for 4-12 weeks is an alternative when the pathogen is susceptible and fluoroquinolones are contraindicated. 4
Doxycycline 100 mg orally twice daily for 4-12 weeks may be used for susceptible organisms, particularly when atypical pathogens are suspected. 4
Refractory Cases
For chronic bacterial prostatitis refractory to conventional oral antimicrobials, consider:
- Fosfomycin as a repurposed agent for multidrug-resistant pathogens 4, 5
- Direct antimicrobial injections into the prostate 5
- Surgical removal of infected prostatic tissue 5
- Chronic oral antibiotic suppression 5
- Novel bacteriophage therapy targeting antibiotic-resistant bacteria (emerging therapy) 5
Repeated use of quinolones should be avoided if there is no obvious symptomatic benefit from infection control or cultures do not support an infectious cause. 6
Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS)
CP/CPPS requires a multimodal, symptom-based treatment approach rather than antimicrobials, because it is not caused by culturable bacteria. 1, 2
First-Line Therapy for Urinary Symptoms
α-Blockers (tamsulosin, alfuzosin) are first-line therapy for CP/CPPS with voiding lower urinary tract symptoms, achieving a NIH-CPSI score improvement of -10.8 to -4.8 points compared to placebo. 2, 7
Additional Pharmacologic Options
Other oral therapies provide modest symptom improvement:
- Anti-inflammatory drugs (ibuprofen): NIH-CPSI score difference -2.5 to -1.7 2
- Pregabalin: NIH-CPSI score difference -2.4 2
- Pollen extract: NIH-CPSI score difference -2.49 2
Early use of treatments targeting neuropathic pain should be considered for patients who do not respond to initial measures. 6
Multidisciplinary Approach
A multidisciplinary team approach is recommended, involving urologists, pain specialists, nurse specialists, specialist physiotherapists, general practitioners, cognitive behavioral therapists/psychologists, and sexual health specialists. 6, 7
Patients should be fully informed about possible underlying causes and treatment options, including an explanation of the chronic pain cycle. 6
Referral to specialist services should be considered early for patients who do not respond to initial measures. 6
Special Considerations and Common Pitfalls
All urinary tract infections in men are classified as complicated and require 7-14 days of therapy; a 14-day course is preferred when prostatitis cannot be excluded. 1
Do not treat asymptomatic bacteriuria in men, as this promotes resistance without clinical benefit; therapy is indicated only for symptomatic infections. 1
Obtain urine culture with susceptibility testing before initiating antibiotics in all cases of suspected bacterial prostatitis to enable targeted therapy. 1
Evaluate for underlying urological abnormalities (obstruction, incomplete voiding, indwelling devices, recent instrumentation, diabetes, immunosuppression) because antimicrobial therapy alone is insufficient without addressing these factors. 1
For men younger than 35 years, test for atypical pathogens (Chlamydia trachomatis, Mycoplasma species) and provide appropriate coverage. 1
Stopping antibiotics prematurely in acute bacterial prostatitis can lead to chronic bacterial prostatitis; complete the full 2-4 week course. 1
Nitrofurantoin and fosfomycin should be avoided for prostatitis because of insufficient prostatic tissue penetration. 1